Filtricine, Inc.

Filtricine, Inc. is a clinical-stage biotechnology company located in the San Francisco Bay Area.

It focuses on developing innovative food-based products aimed at cancer care and disease control. The company employs a nutrition-based approach known as Targeted Nutrients Deprivation, which is designed to support patients while targeting cancer cells. The main product offered by Filtricine is Tality, a proprietary medical food and meal-replacement regimen specifically for cancer patients. Tality is currently being investigated in clinical studies and has been utilized in a Stanford-sponsored prostate cancer clinical trial. Filtricine aims to help patients maintain proper nutrition during their treatment and has plans to expand its product offerings to address other common diseases in the future. Filtricine's target audience includes cancer patients, hospitals, clinics, and healthcare institutions that may use or distribute its products. The company is dedicated to serving the North American cancer-care market and is committed to improving patient outcomes through its nutritional solutions.